Toth Financial Advisory Corp Increases Stake in argenex SE $ARGX

Toth Financial Advisory Corp lifted its holdings in shares of argenex SE (NASDAQ:ARGX) by 812.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,323 shares of the company’s stock after buying an additional 1,178 shares during the quarter. Toth Financial Advisory Corp’s holdings in argenex were worth $1,227,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in ARGX. Valeo Financial Advisors LLC lifted its stake in argenex by 5.1% in the second quarter. Valeo Financial Advisors LLC now owns 1,077 shares of the company’s stock worth $999,000 after purchasing an additional 52 shares during the last quarter. Trust Point Inc. grew its stake in shares of argenex by 10.3% during the second quarter. Trust Point Inc. now owns 503 shares of the company’s stock valued at $467,000 after buying an additional 47 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of argenex by 11.8% in the second quarter. Assenagon Asset Management S.A. now owns 16,531 shares of the company’s stock worth $15,337,000 after buying an additional 1,745 shares during the period. GAMMA Investing LLC increased its holdings in shares of argenex by 24.6% in the second quarter. GAMMA Investing LLC now owns 349 shares of the company’s stock worth $324,000 after buying an additional 69 shares during the period. Finally, Harbor Investment Advisory LLC increased its holdings in shares of argenex by 78.3% in the second quarter. Harbor Investment Advisory LLC now owns 1,157 shares of the company’s stock worth $1,073,000 after buying an additional 508 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Up 1.3%

NASDAQ:ARGX opened at $876.00 on Thursday. The firm’s fifty day simple moving average is $882.24 and its 200 day simple moving average is $820.70. The stock has a market cap of $54.80 billion, a P/E ratio of 33.64, a price-to-earnings-growth ratio of 1.07 and a beta of 0.46. argenex SE has a twelve month low of $637.04 and a twelve month high of $953.58.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. On average, analysts expect that argenex SE will post 28.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the subject of several analyst reports. Weiss Ratings cut argenex from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 23rd. Citizens Jmp lowered their price objective on argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a research report on Friday, July 24th. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research note on Saturday, July 25th. Royal Bank Of Canada raised their target price on shares of argenex from $945.00 to $1,025.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Guggenheim began coverage on shares of argenex in a research note on Tuesday, August 4th. They issued a “buy” rating and a $1,185.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, argenex has an average rating of “Moderate Buy” and an average price target of $1,056.89.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.